Es gab 50 kürzliche Insider-Transaktionen für Zosano Pharma Corporation (ZSAN), darunter 38 Käufe und 11 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $5.29M und die gesamten Insider-Verkäufe auf $38.93K.
Bedeutende Insider mit kürzlicher Aktivität umfassen Lo Steven, Matthews Christine, Kellerman Donald J. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — ZSAN
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2022-06-06 |
Lo Steven |
Chief Executive Officer |
Informierter Verkauf |
442 |
$0.71 |
$313.82 |
13,163 |
| 2022-06-06 |
Matthews Christine |
Chief Financial Officer |
Informierter Verkauf |
82 |
$0.71 |
$58.22 |
4,183 |
| 2022-03-31 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
Informierter Verkauf |
4,006 |
$0.21 |
$841.66 |
56,331 |
| 2022-03-31 |
Lo Steven |
Chief Executive Officer |
Informierter Verkauf |
23,633 |
$0.21 |
$4.97K |
460,709 |
| 2022-03-31 |
Matthews Christine |
Chief Financial Officer |
Informierter Verkauf |
8,116 |
$0.21 |
$1.71K |
146,425 |
| 2021-11-23 |
Greathouse Kenneth |
Director |
Informierter Verkauf |
10,000 |
$0.60 |
$6.02K |
43,500 |
| 2021-10-15 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU-Zuteilung |
20,000 |
$0.63 |
$12.68K |
20,000 |
| 2021-10-15 |
Lo Steven |
Chief Executive Officer |
RSU-Zuteilung |
237,500 |
$0.63 |
$150.62K |
237,500 |
| 2021-10-15 |
Matthews Christine |
Chief Financial Officer |
RSU-Zuteilung |
112,500 |
$0.63 |
$71.35K |
112,500 |
| 2021-06-10 |
Greathouse Kenneth |
Director |
RSU-Zuteilung |
30,000 |
$0.93 |
$27.95K |
30,000 |
| 2021-06-10 |
Elms Steve |
Director |
RSU-Zuteilung |
15,000 |
- |
- |
22,500 |
| 2021-06-10 |
Xanthopoulos Kleanthis G |
Director |
RSU-Zuteilung |
15,000 |
- |
- |
23,596 |
| 2021-06-10 |
Hagan Joseph P |
Director |
RSU-Zuteilung |
15,000 |
- |
- |
22,500 |
| 2021-06-04 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
Informierter Verkauf |
1,709 |
$0.81 |
$1.38K |
50,337 |
| 2021-06-04 |
Lo Steven |
Chief Executive Officer |
Informierter Verkauf |
13,158 |
$0.81 |
$10.59K |
365,592 |
| 2021-06-04 |
Lewis Hayley |
See Remarks |
Informierter Verkauf |
1,709 |
$0.81 |
$1.38K |
49,779 |
| 2021-06-04 |
Matthews Christine |
Chief Financial Officer |
Informierter Verkauf |
1,709 |
$0.81 |
$1.38K |
98,291 |
| 2021-05-17 |
Greathouse Kenneth |
Director |
RSU-Zuteilung |
21,000 |
$0.73 |
$15.31K |
38,500 |
| 2021-03-30 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU-Zuteilung |
32,500 |
- |
- |
52,046 |
| 2021-03-30 |
Lo Steven |
Chief Executive Officer |
RSU-Zuteilung |
232,500 |
- |
- |
378,750 |
| 2021-03-30 |
Lewis Hayley |
See Remarks |
RSU-Zuteilung |
32,500 |
- |
- |
51,488 |
| 2021-03-30 |
Matthews Christine |
Chief Financial Officer |
RSU-Zuteilung |
81,250 |
- |
- |
100,000 |
| 2021-03-18 |
Lo Steven |
Chief Executive Officer |
RSU-Zuteilung |
450,000 |
$1.37 |
$616.5K |
450,000 |
| 2020-06-25 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU-Zuteilung |
18,750 |
- |
- |
19,546 |
| 2020-06-25 |
Greathouse Kenneth |
Director |
RSU-Zuteilung |
7,500 |
- |
- |
17,500 |
| 2020-06-25 |
Walker John Peter |
Director |
RSU-Zuteilung |
7,500 |
- |
- |
116,511 |
| 2020-06-25 |
Elms Steve |
Director |
RSU-Zuteilung |
7,500 |
- |
- |
7,500 |
| 2020-06-25 |
Xanthopoulos Kleanthis G |
Director |
RSU-Zuteilung |
7,500 |
- |
- |
8,596 |
| 2020-06-25 |
Hagan Joseph P |
Director |
RSU-Zuteilung |
7,500 |
- |
- |
7,500 |
| 2020-06-25 |
Lo Steven |
Chief Executive Officer |
RSU-Zuteilung |
146,250 |
- |
- |
146,250 |
| 2020-06-25 |
Lewis Hayley |
See Remarks |
RSU-Zuteilung |
18,750 |
- |
- |
18,988 |
| 2020-06-25 |
Matthews Christine |
Chief Financial Officer |
RSU-Zuteilung |
18,750 |
- |
- |
18,750 |
| 2020-06-03 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU-Zuteilung |
37,500 |
$1.01 |
$37.88K |
37,500 |
| 2020-06-03 |
Greathouse Kenneth |
Director |
RSU-Zuteilung |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Walker John Peter |
Director |
RSU-Zuteilung |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Elms Steve |
Director |
RSU-Zuteilung |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Xanthopoulos Kleanthis G |
Director |
RSU-Zuteilung |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Hagan Joseph P |
Director |
RSU-Zuteilung |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Lo Steven |
Chief Executive Officer |
RSU-Zuteilung |
292,500 |
$1.01 |
$295.43K |
292,500 |
| 2020-06-03 |
Lewis Hayley |
See Remarks |
RSU-Zuteilung |
37,500 |
$1.01 |
$37.88K |
37,500 |
| 2020-06-03 |
Matthews Christine |
Chief Financial Officer |
RSU-Zuteilung |
37,500 |
$1.01 |
$37.88K |
37,500 |
| 2020-05-01 |
Matthews Christine |
Chief Financial Officer |
RSU-Zuteilung |
35,000 |
$0.70 |
$24.54K |
35,000 |
| 2020-02-03 |
Matthews Christine |
See Remarks |
Veräußerung |
3,750 |
$2.75 |
$10.31K |
- |
| 2019-12-02 |
Aisling Capital Iv, Lp |
10 Percent Owner |
RSU-Zuteilung |
689,655 |
$1.45 |
$1000K |
2,718,226 |
| 2019-10-21 |
Lo Steven |
Chief Executive Officer |
Unbekannt |
- |
- |
- |
- |
| 2019-10-21 |
Lo Steven |
Chief Executive Officer |
RSU-Zuteilung |
450,000 |
$1.94 |
$873K |
450,000 |
| 2019-06-11 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU-Zuteilung |
30,000 |
$2.75 |
$82.5K |
30,000 |
| 2019-06-11 |
Lewis Hayley |
See Remarks |
RSU-Zuteilung |
30,000 |
$2.75 |
$82.5K |
30,000 |
| 2019-04-11 |
Aisling Capital Iv, Lp |
10 Percent Owner |
RSU-Zuteilung |
428,571 |
$3.50 |
$1.5M |
2,028,571 |
| 2019-04-11 |
Walker John Peter |
President & CEO |
Informierter Kauf |
100,000 |
$3.50 |
$350K |
280,228 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall